This study was supported by research funding from the National Natural Science Foundation of China (82230006, 82300169, 81970130, 82470159, and U24A20678), the Overseas Expertise Introduction Project ...
Acute promyelocytic leukemia (APL) is classically driven by the PML-RARA fusion oncogene and characterized by a maturation arrest of myeloid precursors. Variant APL (vAPL) with alternative RARA ...
aHuman Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA bLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer ...
Patients who do not carry any of the aforementioned defining genetic alterations or whose pretreatment cytogenetic investigation fails are categorized into AML subtypes defined by differentiation. 7 ...
The three approved JAK inhibitors (ruxolitinib, fedratinib, and pacritinib) are the cornerstones of management for symptomatic myelofibrosis. Numerous novel agents in development for myelofibrosis, ...
Leukemia is a malignant disease of hematopoietic tissue characterized by the differentiation arrest and malignant proliferation of immature hematopoietic precursor cells in bone marrow. ERG ...
The APL2012 trial is currently the largest randomized, multicenter clinical study of APL based on ATRA-ATO treatment with risk stratification. We enrolled 855 newly diagnosed APL patients during ...
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2 The ...
All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results